The U.S. Food and Drug Administration approved a labeling supplement for Glaukos Corporation’s iDose TR intracameral drug‑delivery system on January 28 2026, allowing the device to be re‑implanted in the same patient. The approval removes the single‑use restriction that had limited the implant to one administration, thereby expanding the addressable market and enabling a multi‑cycle revenue model for each patient.
Clinical data supporting the decision included a Phase 3 study that followed patients for three years and reported no clinically significant corneal endothelial cell loss, as well as an exchange trial that demonstrated safety and tolerability of a second iDose TR implant over a 12‑month period. These results reinforced the FDA’s confidence in the device’s long‑term safety profile and supported the repeat‑treatment labeling.
Glaukos reported preliminary fourth‑quarter 2025 revenue of approximately $143 million, a 36% year‑over‑year increase that aligned with the company’s guidance. The company reaffirmed its full‑year 2026 revenue outlook, indicating continued confidence in the growth trajectory of its glaucoma portfolio. The approval is expected to accelerate the adoption of the iDose TR annuity model, which has already proven successful in the single‑use market.
Analysts upgraded their outlooks following the announcement, raising price targets and maintaining overweight ratings. The market reaction reflected the perceived value of the expanded patient base and the validation of the device’s safety record, which together strengthen Glaukos’ competitive position against traditional topical therapies and other MIGS devices.
Thomas Burns, Glaukos’ chairman and CEO, said the labeling enhancement “will help expand access for patients who may benefit from repeat treatment and provide physicians with greater flexibility in managing their glaucoma patients over time.” He added that the approval further validates the company’s leading position in delivering sustained procedural pharmaceutical alternatives to eye drops.
The approval positions Glaukos to capture a larger share of the glaucoma treatment market, where patient adherence to topical medications remains a challenge. By enabling repeat administrations, the company can generate recurring revenue from a single implant, improving cash flow predictability. The move also strengthens Glaukos’ competitive moat against other MIGS solutions such as iStent and iStent inject, as well as emerging pharmacologic therapies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.